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Background: Type 2 diabetes mellitus (DM), characterized by peripheral insulin resistance, is the most common
form of diabetes. Probiotics are live micro-organisms that, when administered in adequate amounts, confer
delaying effect on DM development. In this study, the effects Lactobacillus reuteri GMNL-263 (Lr263), a new
probiotic strain developed by our laboratory, on insulin resistance and the development of hepatic steatosis in
high-fructose fed rats were explored. Furthermore, the relevant regulatory pathways involved were also
investigated.
Method: Male Sprague–Dawley rats were fed a high-fructose diet with or without Lr263 administration for 14
weeks. The composition of fecal microbiota, oral glucose tolerance, glycated haemoglobin, insulin, leptin, C-peptide,
and incretins were measured. The markers of liver injury, serum and hepatic lipids profile, activity of hepatic
antioxidant enzyme, and proinflammatory cytokines in adipose tissue were investigated. Additionally, the expression
of hepatic lipogenic genes and insulin signaling related genes in adipose tissue were also studied. Liver sections
were examined for hepatic steatosis using hematoxylin-eosin staining.
Results: The levels of serum glucose, insulin, leptin, C-peptide, glycated hemoglobin, GLP-1, liver injury markers,
lipid profile in serum and liver were significantly increased in high-fructose-fed rats. However, after Lr263
administration, the elevation of these parameters was significantly suppressed. Feeding of Lr263 reversed the
decreased number of bifidobacterium species and lactobacillus species and increased number of clostridium species
induced by high fructose treatment. The decreased activities of hepatic antioxidant enzymes in HFD rats were
dramatically reversed by Lr263 treatment. Concentrations of IL-6 and TNF-α in adipose tissue which were elevated
in high fructose treatment were markedly decreased after Lr263 feeding. Decreased levels of PPAR-γ and GLUT4
mRNA after high fructose treatment were significantly enhanced by Lr263 administration. Lr263 consumption
normalized the increased lipogenic gene (Srebp-1c, FAS, and Elvol6) expressions stimulated by high fructose.
Administration of Lr263 significantly ameliorated hepatic steatosis observed in high fructose treated rats.
Conclusion: Our study provided evidences clarifying the effectiveness of Lr263 on reducing insulin resistance as
well as hepatic steatosis formation in high-fructose-fed rats and suggested that Lr263 may be a promising
therapeutic agent in treating type 2 diabetes.
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Diabetes is a chronic global health problem, however, its
etiology still remains elusive. The development of diabetic
complications is a major cause of premature morbidity
and mortality in diabetic patients [1]. There are two main
forms of diabetes namely type 1 diabetes and type 2 dia-
betes [2]. Type 1 diabetes is typically caused by an auto-
immune assault against the β-cells, resulting in lack of
insulin secretion [3]. Type 2 diabetes is the most common
form of diabetes comprising about 80% of all diabetic
population characterizing by insulin resistance, dysli-
pidemia, and hyperglycemia [4-6]. The World Health
Organization has predicted that developing countries
would have to bear the major burden of this disease. It has
been estimated that there will be a 42% increase from 51
million individuals in 1995 to 72 million individuals in
2025 affected in the developed countries [7]. However, in
developing countries these figures are much higher and
are expected to show 170% increase from 84 to 228 mil-
lion [7]. Insulin resistance, a major abnormality underlying
type 2 diabetes mellitus, is defined as the pathophysio-
logical condition reducing insulin responsiveness in liver,
muscle, and adipose tissue [8,9]. Aberrations of metabol-
ism caused by insulin resistance may increase levels of cir-
culating free fatty acids and liver fat accumulation, which
then leads to liver inflammation and fibrosis [10]. Further-
more, high levels of free fatty acids induce the overex-
pression of cytochrome P450 (CYP) 2E1 and increase
oxidative stress via lipid peroxidation, which may lead to
liver injury [11].
Intestinal flora has been shown to influence human
health such as immuno-stimulation, improved digestion
and absorption, vitamin synthesis, inhibition of the
growth of potential pathogens, cholesterol reduction,
and lowering of gas distension [12-14]. The best way for
controlling the flora balance in intestine is achieved by
intake of probiotics, which is thought to be effective in
lifestyle-related diseases [12,13]. Probiotics are defined
as nonpathogenic live microorganisms that, when inges-
ted adequately, confer health benefits to the host. The
exact mechanisms by which probiotics exert their effect-
iveness on diabetes and its related complications are still
inconclusive. Recently, probiotics have been reported to
prevent or delay the onset of diabetes in various experi-
mental models including chemical-induced, diet-induced,
and genetically mutated animals [15-18]. Among these
probiotics, Lactobacillus species, constituting the major
part of the lactic acid bacteria group, have been reported
to exhibit prominent effects on the management of dia-
betes and its complications. More specifically, oral admi-
nistration of Lactobacillus casei exhibited a preventive
effect on the elevation of plasma glucose and reduction of
plasma insulin level resulted from destruction of pancre-
atic β-cells in Non-obese diabetic mice [15]. Yadav et al.[19] demonstrated that, Dahi (containing probiotic Lacto-
bacillus acidophilus and Lactobacillus casei), a traditional
India fermented milk product, demonstrated an inhibitory
effect on development of glucose intolerance, hypergly-
cemia, hyperinsulinemia, dyslipidemia, and oxidative stress
in high fructose-induced diabetic rats. The same treat-
ments significantly suppressed the depletion of insulin as
well as preserving diabetic dyslipidemia, and inhibited lipid
peroxidation and nitrite formation in streptozotocin-
induced diabetic rats [20]. Furthermore, Lactobacillus GG
displayed an antidiabetic effect on neonatal streptozotocin-
induced diabetic rats by lowering the blood HbA1c level
and improving glucose tolerance [17]. These results im-
plied that administration of different Lactobacillus strains
may confer antidiabetic effect as well as delaying diabetes
onset.
Lactobacillus reuteri GMNL-263 (Lr263) is a represen-
tative probiotic bacteria that is commercially available as
a healthy food in Taiwan. Our previous study demon-
strated that oral administration of Lr263 has a preven-
tive effect on the elevation of plasma glucose and renal
fibrosis in streptozotocin-induced diabetic rats [21].
However, the effects of Lr263 on type 2 diabetes and its
related complications remained unraveled. Thus, the
present study was set out to explore the effect of oral
administration of Lr263 on insulin resistance and the as-
sociated metabolic syndrome using a well-established
animal model of type 2 diabetes characterized by insulin
resistance, metabolic syndrome, and oxidative stress.
Furthermore, the possible regulatory pathways involved
were also investigated.
Materials and Methods
Preparation of Lactobacillus reuteri GMNL-263
Lr263 was obtained from the culture collection of the
GenMont Biotech Incorporation (Taiwan). Lactobacilli
microorganisms for oral administration were prepared
from overnight cultures of Lactobacilli and subcultured
in Man Rogosa Sharpe (MRS) broth (Difco Laboratories,
Detroit, MI, USA) at 37°C. These microorganisms were
collected by centrifugation to remove the MRS broth
and suspended in sterile water at a concentration of 109
CFU/ml.
Animal model
Male Sprague–Dawley rats (BioLASCO Taiwan Co.,
Ltd., Yi-Lan, Taiwan) were housed in plastic cages in an
animal room maintained with a 12 h light–dark cycle at
24 ± 1°C and 50% humidity. Animals were allowed free
access to water and food throughout the study. The ani-
mals used in the present study were cared for according
to the principles and guidelines of the Institutional Animal
Ethical Committee (IAEC). All procedures were approved
by the IAEC.
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Animals used in the study were divided into (1) control
group (Control; n = 6) that consumed a standard 65%
cornstarch diet (PMI Nutrition International, Brentwood,
MO, USA), (2) high fructose-diet group (HFD; n = 6) that
consumed a 65% fructose diet (Harlan Laboratories, Inc.,
California, USA), and (3) HFD + Lr263 group (n = 6)
which were simultaneously fed with the 65% fructose diet
and Lr263 (2 × 109 CFU/rat) every day for 14 weeks ex-
cept for the days before oral glucose tolerance test
(OGTT) and blood collection. Lr263 was administered or-
ally to rats by an oral gavage.
Body weight and food consumption
The body weight of each rat was measured pre-test,
weekly thereafter and at sacrifice after fasting. Food con-
sumption for each rat was determined weekly.
Enumeration of feces microbiota using plate culture
The cultivation of intestinal microbiota was performed
according to the method previously described by
Montesi et al. [22] with modifications. Briefly, fresh fecal
samples were collected in sterile tubes and stored in ali-
quots at −80°Cfor a maximum of 1 month until process-
ing. Samples were homogenized in a sterile peptone-salt
solution (enzymatic digest of casein 1 g/L, sodium chlor-
ide 8.5 g/L). Serial 10-fold dilutions were prepared and
volumes of 100 μl of 3 appropriate dilutions were loaded
onto the surface of plates in duplicate which contained
the following agar media: Wilkins-Chalgren agar (Oxoid,
Basingstoke, UK) supplemented with MRS (Oxoid) for
bifidobacteria and lactobacilli; supplemented with SPS
(Oxoid) for clostridia. All these plates were incubated
anaerobically at 37°C for 4–5 days. Representative col-
onies of each selective medium were identified to genus
level by standard bacteriological methods including
Gram stain, morphology, and biochemical reactions. The
number of colony counting for each microbiota species
was expressed as log CFU/g fecal content.
Blood and tissue sample collection
At the end of the experiments, the animals were sacri-
ficed by CO2 anesthesia. The blood samples were col-
lected and centrifuged at 4000 × g for 10 min at 4°C and
then stored at −80°C. Liver, adipose tissue, and kidney
were weighted and washed with ice-cold saline, then
were stored at −80°C until used.
Oral glucose tolerance test
Oral glucose tolerance tests were performed at 0, 4, 8
and 14 weeks after treatments. The diets were removed
from animal cages for 12 h before the administration of
an oral glucose load (2 g/kg of body weight) by an oral
gavage. Blood samples were collected from the tail veinat 0, 15, 30, 60, 90, and 120 min after glucose adminis-
tration. Glucose concentrations were determined by glu-
cometer (TaiDoc Technology Co, Taipei, Taiwan). The
total glucose areas under the curve (AUCglucose) between
0 and 120 min represented the magnitude of the glucose
response and were calculated as described previously [23].
Measurement of serum/plasma glucose, insulin, leptin,
C-peptide, active Glucagon-like peptide-1 (GLP-1), and
total Gastric inhibitory polypeptide (GIP) concentrations
Serum glucose concentrations were determined by gluco-
meter (TaiDoc Technology Co, Taipei, Taiwan). Serum
levels of insulin, leptin, and C-peptide, plasma levels of ac-
tive GLP-1 and total GIP were measured by commercial
ELISA Kit (Millipore, MA, USA) according to the manu-
facturer’s instructions. For the measurement of active
GLP-1 and total GIP, blood samples were collected and
immediately subjected to plasma separation in centrifuge
tubes containing EDTA-2Na and aprotinin. The detection
limits of insulin, leptin, C-peptide, GLP-1, and GIP assays
were 0.2 ng/ml, 0.2 ng/ml, 25.0 pM, 4.1 pM, and 8.2 pg/ml,
respectively.
Measurement of HbA1c
The whole blood samples of experimental rats at week 0,
4, 8, and 14 were collected and subjected to HbA1c deter-
mination. The levels of HbA1c were measured by the
DCA-2000 system (Ames, Bayer Diagnostics, Basingstoke,
England). The method was based on immunological de-
tection of glycated Hb. The monoclonal antibody used
was specific for an NH2-terminal amino-acid sequence in
the beta chain of glycated Hb, and thus did not bind to
other glycated Hbs such as HbAla or HbAlb. Both glucose
and this specific amino-acid sequence were necessary for
antibody binding. The monoclonal antibody was supplied
bound to latex beads and was agglutinated by the second
reagent in the absence of HbAlc. Glycated Hb thus com-
peted with the agglutinating agent for antibody binding
sites, thereby blocking agglutination. This agglutination
reaction caused increased light-scattering which was mea-
sured as an increase in absorbance at 531 nm. The
amount of HbAlc was calculated as a fraction of total Hb.
Ratio of HbA1c to total hemoglobin was calculated and
reported directly as % HbA1c.
Biochemical parameters analysis
Serum biochemical parameters including triglyceride
(TG) (detection limit was 3 mg/dl), low density lipopro-
tein (LDL) (detection limit was 5 mg/dl), cholesterol (de-
tection limit was 3 mg/dl), aspartate aminotransferase
(AST) (detection limit was 0.04 U/dl), and alanine ami-
notransferase (ALT) (detection limit was 0.04 U/dl) were
analyzed using an automatic clinical analyzer (Hitachi
High-Technologies Corporation, Tokyo, Japan).
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Liver samples were collected and homogenized in 4 vol-
umes of 56 mM Tris/HCl buffer (pH 7.4) containing
1.15% potassium chloride and then centrifuged at 10,000 g
for 15 min. The supernatants were collected and stored
at −80°C. The concentrations of protein in supernatants
were determined using a commercial kit (Bio-Rad)
according to the manufacturer’s instructions. The activity
of superoxide dismutase (SOD) and glutathione reductase
(GR) in the liver were evaluated using commercial SOD
assay kit (Sigma), and glutathione reductase assay kit
(Sigma), respectively, according to the manufacturer’s in-
struction. The enzyme activity of SOD and GR were
expressed as U/mg protein. The detection limit of SOD
and GR assay were 0.001U/ml and 0.003 U/ml.
Measurement of TNF-α and IL-6 levels in adipose tissue
The adipose tissues (0.1-0.3 g) were homogenized in
RIPA buffer (0.625% Nonidet P-40, 0.625% sodium
deoxycholate, 6.25 mM sodium phosphate, and 1 mM
ethylenediamine tetraacetic acid at pH 7.4) containing
10 μg/ml of a protease inhibitor cocktail (Sigma, St.
Louis, Missouri, USA). Homogenates were centrifuged
at 12,000 g for 10 min at 4°C. Then the supernatants
were collected and subjected to protein concentration
determinations using a commercial kit (Bio-Rad DC
Protein Assay, Bio-Rad, CA, USA). Quantitative assess-
ment of TNF-α and IL-6 protein levels were carried out
by commercial ELISA kits (DuoSet ELISA, R&D Sys-
tems, Minneapolis, MN) according to the manufacturer’s
instructions.
Measurement of hepatic lipid
To quantify hepatic triglyceride and cholesterol content,
liver tissues (100 mg) were homogenized in ice-cold 20
mmol/L Tris–HCl, 150 mmol/L NaCl, 2 mmol/L EDTA,
and 1% Triton X-100, pH 7.5. The lipids were extracted
by shaking in cold chloroform : methanol (v/v, 2:1) as
previously described by Folch et al. [24]. Liver triglycer-
ide and total cholesterol were measured by enzymatic
methods using commercial kits (Wako Pure Chemical,
Dallas, Texas, USA). The detection limit of triglyceride
and total cholesterol were 3 mg/dl.
Real time quantitative polymerase chain reaction (Real
time PCR)
Total RNA of the adipose tissue (for PPARγ, GLUT1, and
GLUT4) and hepatic tissue (for Elvol6, FAS, and Srebp-1c
mRNA) of each rat were extracted using TRI Reagent
(Invitrogen, Carlsbad, CA, USA). Then the extracted RNA
was treated with TUBRO DNase (Applied Biosystems,
Foster City, CA, USA) for 25 min at 37°C. Two micro-
grams of TUBRO DNase-treated RNA were reverse tran-
scribed using High Capacity RNA-to-cDNA kit (AppliedBiosystems). The cDNA samples were then diluted with
nuclease-free water to a final concentration equivalent to
20 ng/μL RNA input, and 6 μL of these dilutions were
then subjected to 40 cycles of quantitative Real-time PCR
with the SYBR Green Master Mix (Roche Applied Science,
Indianapolis, IN, USA) was performed using ABI Prism
7500 Sequence Detection System (Applied Biosystems).
Primers for PPAR-γ, sense: 5’-TGCAGGTGATCAAG
AAGACG-3’; antisense: 5’-TGGAAGAAGGGAAATGTT





5’-AGCGCAGAAAACAGGAAAGACT-3’; FAS, sense: 5’-
GGCATCATTGGGCACTCCTT-3’; antisense: 5’- GCTGC
AAGCACAGCCTCTCT-3’, and Srebp-1c, sense: 5' -GGA
GCCATGGATTGCACTTT- 3'; antisense: 5' TCAAATA
GGCCAGGGAAGTCA 3' were tested alongside the nor-
malizing gene β-actin (sense: 50-TCTGTGTGGATTGGT
GGCTCT-30; antisense: 50-GACTC ATCGTACTCCTGCT
TGCT-30). The fluorescent signals were collected during
extension phase, Ct values of the sample were calculated,
and the transcript levels were analyzed by 2-ΔΔCt method.
Histological analysis
Livers isolated from rats were fixed in 10% formalin and
embedded in paraffin. Three-micrometer thick sections
were obtained, and deparaffinized in xylene. The sections
were stained with hematoxylin-eosin. The results of stain-
ing were viewed and photographed with an Olympus
microscope (Olympus Corporation, Tokyo, Japan).
Statistical analysis
Results were expressed as mean ± standard deviation
(SD). Statistical analysis was performed using the
ANOVA and Duncan’s multiple-range tests. Difference
was considered to be significant at p < 0.05.
Results
Effects of Lr263 on body weight, food intake, various
tissue weights, and homeostasis model assessment-
estimated insulin resistance (HOMA-IR) in high-
fructose-diet rats
As shown in Table 1, the body weight, liver weight, adi-
pose tissue weight, and HOMA-IR in the HFD group
were significantly increased compared to control group.
After administration of Lr263, an increase in body
weight, liver weight, adipose tissue weight, and HOMA-
IR in HFD group were significantly decreased and
reached the levels similar to the control group. There
were no significant changes in kidney weight and food
intake among the three groups.
Table 1 Effects of Lactobacillus reuteri GMNL-263 on body weight, food intake, various tissue weights, and HOMA-IR
index in high-fructose-diet rats
Control HFD HFD+Lr263
Body weight (g) 484.83 ± 29.69 572.67 ± 40.81# 502.83 ± 35.91*
Food intake (g/day/rat) 28.94 ± 1.35 27.45 ± 1.88 27.54 ± 1.16
Liver weight (% body weight) 2.65 ± 0.26 2.93 ± 0.09# 2.53 ± 0.07*
Kidney weight (% body weight) 0.71 ± 0.06 0.713 ± 0.01 0.71 ± 0.02
Adipose tissue weight (% body weight) 5.10 ± 0.80 8.29 ± 2.10# 6.85 ± 0.16#
HOMA-IR 5.24 ± 1.68 19.93 ± 4.51# 8.88 ± 1.21*
# p<0.05 compared with control group; * p<0.05 compared with HFD group.
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high-fructose-diet rats
Bifidobacteria and Lactobacilli have been regarded as
beneficial microflora species, whereas some species, Clos-
tridia for example, would be harmful as a consequence of
their metabolic activities. The number of Bifidobacteria,
Lactobacilli, and Clostridia in control group were regarded
as 100% for comparison. Our present results indicated that
the number of Bifidobacteria, Lactobacilli, and Clostridia
in HFD group were 103.2 ± 6.4%, 97.4 ± 3.8%, and 130.1 ±
5.9%, respectively. These results revealed that no signifi-
cant change on the number of Bifidobacteria and Lactoba-
cilli in HFD group was noticed as compared to control
group. However, the number of Clostridia in HFD group
was significantly higher than that of control group. After 14
weeks of Lr263 treatment, the number of Bifidobacteria,
Lactobacilli, and Clostridia were 126.7 ± 3.4%, 135.4 ±
7.8%, and 102.5 ± 4.9%, respectively. These results demon-
strated that administration of Lr263 significantly increased
the number of Bifidobacteria as well as Lactobacilli and
decreased the number of Clostridia when compared to
HFD group.
Effects of Lr263 on oral glucose tolerance test (OGTT) in
high-fructose-diet rats
The results of OGTT after 14 weeks treatment were
shown in Figure 1. There were no significant differences
on blood glucose levels among the three groups within 8
weeks after treatment (data not shown). However, a
marked increase in blood glucose concentrations at 15,
30, and 60 min after glucose loading in HFD group were
noticed. This increase in serum glucose levels in HFD
group was significantly decreased after administration of
Lr263 (Figure 1A). The AUCglucose values shown in
Figure 1B clearly reflected the inhibitory effect of Lr263
on blood glucose elevation by high fructose treatment.
Effects of Lr263 on serum levels of glycated haemoglobin,
glucose, insulin, leptin, C-peptide, and plasma levels of
active GLP-1 and total GIP in high-fructose-diet rats
The levels of HbA1c, an important indicator for glucose
metabolism, were markedly increased at 8 and 14 weeksin HFD group when compared to control group. How-
ever, the elevations of HbA1c in HFD group at 8 and
14 weeks were downregulated by administration of
Lr263 (Figure 2A). In addition, the fasting serum con-
centrations of glucose, insulin, leptin, and C-peptide
were significantly higher in HFD group than those of
control group. However, the increase in serum concen-
trations of glucose, insulin, leptin, and C-peptide in
HFD rats were significantly decreased after administra-
tion of Lr263 (Figure 2B). As shown in Figure 2C, a sig-
nificant decrease in active GLP-1 was observed in HFD
groups as compared to control group. Lr263 adminis-
tration significantly stimulated active GLP-1 expression.
However, the plasma concentration of total GIP, an-
other important member of incretin, was not signifi-
cantly different among the control, HFD, and HFD +
Lr263 groups.Effect of Lr263 on hepatic injury markers and antioxidant
activities in high-fructose-diet rats
Increased serum levels of AST and ALT were found
in HFD group (Figure 3A). These results showed that
long-term high fructose treatment induced damage to
liver cells. However, administration of Lr263 signifi-
cantly lowered the increased AST and ALT levels in
HFD group. The results shown in Figure 3B revealed
that the activities of SOD and glutathione reductase
in rat livers were decreased, respectively, as compa-
red to control group. Administration of Lr263 mar-
kedly upregulated these two antioxidant activities,
which were decreased in HFD group, in rat livers
(Figure 3B).
Effect of Lr263 on adipose tissue inflammatory cytokines
in high-fructose-diet rats
Two important insulin resistance-related inflammatory
cytokines namely TNF-α and IL-6 produced by adipose
tissue were evaluated by commercially available ELISA
kit. As shown in Figure 3C, the concentrations of TNF-α
and IL-6 in HFD group were significantly enhanced as
compared to control group, and this enhancing effect
AB
Figure 1 Effect of Lactobacillus reuteri GMNL-263 on oral glucose tolerance test (OGTT) in high-fructose-diet rats for 14 weeks. The test
was performed at 0, 4, 8, and 14 weeks. The results of OGTT at 14 weeks after treatment were shown in (A). AUCglucose value which represented
the area under the curve of glucose level at 14 weeks after treatment was shown in (B). Data were expressed as mean ± SD (n = 6). Control,
control group; HFD, high fructose diet group; HFD + Lr263, high fructose-treated and Lactobacillus reuteri GMNL-263 group. #p < 0.05 compared
with Control group; *p < 0.05 compared with HFD group.
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Lr263 group).
Effect of Lr263 on serum and hepatic lipid profile in
high-fructose-diet rats
Previous studies indicated that increased levels of TG
and cholesterol were the main predictors and causative
factors for inducing insulin resistance in type 2 diabetes
[25]. In our current results, higher serum levels of LDL,
TG, and cholesterol were noticed in HFD group as com-
pared to control group (Figure 4A). Administration of
Lr263 significantly reduced the increased levels of LDL,
TG, and cholesterol seen in HFD group (Figure 4A). To
examine whether dietary Lr263 can suppress the forma-
tion of hepatic steatosis, the levels of TG and cholesterol
in rat liver cells were performed. Our results demon-
strated that higher levels of hepatic TG and cholesterol
were found in HFD group as compared to control group.
Feeding of Lr263 significantly suppressed the increasedhepatic TG and cholesterol levels in HFD group
(Figure 4B).
Effect of Lr263 on PPARγ, GLUT1, GLUT4, and hepatic
lipogenic gene expressions in high-fructose-diet rats
The PPARγ mRNA, GLUT1 mRNA, and GLUT4 mRNA
expression levels in adipose tissue were shown in
Figure 2D. The PPARγ mRNA, GLUT1 mRNA, and
GLUT4 mRNA levels in adipose tissue were signifi-
cantly decreased in HFD group compared with control
group. Additionally, following the treatment with Lr263
(HFD + Lr263 group), PPARγ mRNA and GLUT4 mRNA
expressions were significantly increased compared with
HFD group. However, the expression of GLUT1 mRNA
showed no significant change between HFD group and
HFD + Lr263 group. Expression of genes involved in
hepatic fatty acid synthesis (Elvol6, FAS, and Srebp-1c)
were induced in rats fed with high fructose diet (HFD
group) compared to control group. Administration of






















































































Figure 2 (See legend on next page.)
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Figure 2 Lactobacillus reuteri GMNL-263 ameliorates insulin resistance and facilitates glucose uptake in high-fructose-diet rats. Effects
of Lactobacillus reuteri GMNL-263 on glycated hemoglobin (HbA1c) (A), glucose metabolism index (including serum glucose, insulin, leptin, and
C-peptide levels) (B), plasma incretin (active GLP-1 and total GIP) concentrations (C), and insulin sensitivity regulation as well as glucose uptake
related genes expression in adipose tissue (PPARγ, GLUT1 and GLUT4) (D) in high-fructose-diet rats. The serum glucose metabolism index, plasma
incretin concentrations, and relevant mRNA were measured at 14 weeks after treatment. The whole blood samples were used for determination
of glycated hemoglobin (HbA1c) at week 0, 4, 8, and 14. Values were expressed as mean ± SD (n = 6). #p < 0.05 compared with Control group;
*p < 0.05 compared with HFD group.
Hsieh et al. Nutrition & Metabolism 2013, 10:35 Page 8 of 14
http://www.nutritionandmetabolism.com/content/10/1/35increased mRNA expressions to near control levels
(Figure 4C).
Effect of Lr263 on hepatic steatosis by histological analysis
In order to verify the efficacy of Lr263 on prevention of
development of hepatic steatosis in rats treated with
high fructose, the histological analysis of rat liver tissues
were performed. As demonstrated in Figure 5, the re-
sults of staining showed prominent diffuse macro-
vesicular steatosis in liver obtained from the HFD group
(Figure 5B) compared to the normal histological appear-
ance of the liver from control group (Figure 5A). How-
ever, administration of Lr263 significantly reversed the
formation of hepatic steatosis induced by high fructose
treatment (Figure 5C).
Discussion
Recent studies on new medications approved for the
treatment of type 2 diabetes are focused on various strat-
egies to prevent and/or delay the onset of type 2 diabetes
and its complications [19,26]. One of these strategies is
the consumption of foods which are low in the glycemic
index with bioactive agents that have been adopted to
prevent or delay the onset of disease [26]. Administra-
tion of probiotics has been reported to be one of the
most widely used approaches to modulate intestinal
microbiota and may subsequently prevent or delay dia-
betes incidence [27]. Cani et al. [28] demonstrated that
Bifidobacterium species improved glucose tolerance,
glucose-induced insulin secretion, normalized inflamma-
tory tone, and reduced the incidence of diabetes. Strains
of lactic acid bacteria are the most common microbes
employed as probiotics. In addition, most probiotic
strains belong to the genus Lactobacillus. Several lines
of evidence indicated that some beneficial effects on hu-
man health were associated with the intake of lactic acid
bacteria [29]. Recently, it has been reported that lactic
acid bacteria have efficacy relating to the progression of
diabetes [20,30]. Previous reports demonstrated that
Clostridium species could trigger the inflammatory
process in human inflammatory bowel diseases [31].
Furthermore, studies from Montesi et al. [22] demon-
strated that the diet containing probiotics was able to
modify the bacterial composition of the caecal content
in rats and to induce a reduction in clostridium species,a bacterial group that was generally considered to be
“non-desirable” members of the intestinal microbiota.
Moreover, a significant reduction in Clostridium species
in human fecal analysis was strongly associated with im-
proving on some metabolic diseases [32]. As shown in
our studies, Lr263 consumption significantly increased
the number of bifidobacteria and lactobacilli, and on the
contrary, decreased the number of Clostridia in the feces
of treated rats when compared to those of the HFD rats.
These results implicated that Lr263 administration
might exert its therapeutic effect on diabetes via increas-
ing the beneficial as well as decreasing the harmful gut
flora species. However, the relevant mechanisms under-
lying this phenomenon needed further investigation.
Previous study revealed that increased weight gain and
fat deposition were responsible for insulin resistance
[33]. In addition, a number of studies reported that a re-
duction of visceral fat in animal models and humans
was associated with increased insulin sensitivity [34].
Our results shown in Table 1 demonstrated that the
body weight, liver weight, and adipose tissue weight in
HFD group were significantly higher than those of
control group. These results were in line with previous
reports [25]. Administration of Lr263 significantly
suppressed the enhancing effect of high-fructose treat-
ment on body weight, liver weight, and adipose tissue
weight. These results implied that reduction of body
weight, liver weight, and adipose tissue weight by Lr263
treatment may be responsible for improving insulin sen-
sitivity in HFD rats. Insulin resistance, determined by
HOMA-IR index, was significantly higher in HFD
rats when compared to control group. However, Lr263
consumption significantly abrogated the increased
HOMA-IR index in HFD rats, further corroborating the
effectiveness of Lr263 on improvement of insulin resist-
ance (Table 1).
Impaired glucose tolerance testing is an important diag-
nostic indicator for type 2 diabetes [35]. Our results from
OGTT indicated that an increase in blood glucose level
was observed after high-fructose-diet feeding. Administra-
tion of Lr263 significantly decreased the blood glucose
levels enhanced by high-fructose treatment. These results
demonstrated that feeding of Lr263 may improve glucose
intolerance and prevent the development of hypergly-

















































































































Figure 3 Lactobacillus reuteri GMNL-263 improves liver injury and oxidative stress in high-fructose-diet rats. Effects of Lactobacillus reuteri
GMNL-263 on expressions of liver injury markers (AST and ALT) (A), hepatic enzymatic activities of antioxidant (SOD and GR) (B), and pro-
inflammatory cytokines (TNF-α and IL-6) (C) in high-fructose-diet rats at the end of the experimental period (14 weeks). The data were expressed
as mean ± SD (n = 6). SOD, speroxide dismutase; GR, glutathione reductase. AST, aspartate aminotransferase; ALT, alanine aminotransferase;
TNF-α, tumor necrosis factorα; IL-6, interleukin 6. #p < 0.05 compared with Control group; *p < 0.05 compared with HFD group.





































































































Figure 4 Lactobacillus reuteri GMNL-263 attenuates lipogenesis in high-fructose-diet rats. Effects of Lactobacillus reuteri GMNL-263 on
expressions of serum lipid profiles (LDL, TG and cholesterol) (A), hepatic lipid profile (TG and cholesterol) (B), and hepatic lipogenic genes (Elvol6,
FAS, and Srebp-1c) (C) in high-fructose-diet rats at 14 weeks after treatment. The results were expressed as mean ± SD (n = 6). LDL, low-density
lipoprotein; TG, triglyceride; Elvol6, fatty acid elongase 6; FAS, fatty acid synthase; Srebp-1c, sterol regulatory element-binding protein 1c.
#p < 0.05 compared with Control group; *p < 0.05 compared with HFD group.
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cose balance, because it reflects the number of glucose
molecules attached to hemoglobin in red blood cells. Simi-
larly, while the HbA1c levels were increased in HFD rats,
feeding Lr263 significantly downregulated the HbA1c
levels enhanced by high fructose treatment. These results
further corroborated the findings in OGTT.
In the obese state, an increase in adipose tissue mass
leads to increased secretion of insulin and leptin into thecirculation [36] resulting in the development of hyper-
insulinemia and hyperleptinemia, respectively [37,38]. In-
sulin and C-peptide are co-secreted from the β-cell in a 1:1
ratio [39]. Unlike insulin, C-peptide has negligible extrac-
tion by the liver and constant peripheral clearance. There-
fore, C-peptide is commonly used in preference to insulin
measurement when assessing β-cell function in clinical
practice [40]. As shown in our current results, the weights
of adipose tissue in HFD rats were higher than those of
AB
C
Figure 5 Effects of Lactobacillus reuteri GMNL-263 on hepatic
steatosis in treated rats. At the end of the experimental period
(14 weeks), the livers obtained from sacrificed rats were subjected to
hematoxylin and eosin staining for evaluation of hepatic steatosis.
The histological sections of rat liver were observed at magnification
200 ×. (A) Liver section from control rat showed normal appearance
of liver cells; (B) Liver section from high-fructose-diets fed rats
showed marked fatty infiltration of hepatocytes with macro- or
micro-vesicular steatosis (black arrow); (C) Liver section from
Lactobacillus reuteri GMNL-263 and high fructose-treated rats
showed mild fatty infiltration of hepatocytes (black arrow). The result
shown here was from one representative experiment of six different
samples with similar results.
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of insulin, C-peptide and leptin in HFD rats seen in our
study. Lr263 feeding abrogated the elevations of glucose,
insulin, C-peptide and leptin levels in HFD rats. Moreover,
previous study indicated that increased leptin was posi-
tively associated with hyperinsulinemia and insulin resist-
ance [41]. Therefore, it was reasonable to propose that
leptin resistance may act synergistically with insulin resist-
ance to result in type 2 diabetes development. Our results
suggested that administration of Lr263 could prevent the
development of type 2 diabetes by normalizing serum
levels of glucose, insulin, C-peptide and leptin. It has long
been recognized that some bioactive agents (hormones)
produced by the gastrointestinal system can modulate the
secretory activities of the islets of Langerhans. These bio-
active agents stimulating the greater insulin secretion from
pancreatic beta cells in response to oral glucose were re-
ferred to as incretins [42]. Two important incretins namely
GIP and GLP-1 secreted by K cells and L cells in the small
intestine, respectively, have been shown to account for as
much as 70% of the insulin secretion immediately after
meal ingestion [43]. Our present results showed that the
secretion of GLP-1 in HFD group was significantly lower
than that of control group. Administration of Lr263
upregulated the decreased GLP-1 level caused by high
fructose treatment. However, the production of GIP among
the control, HFD, and HFD + Lr263 groups were not sig-
nificantly different. Previous studies indicated that aug-
mentation of GLP-1 action was widely used for the
treatment of type 2 diabetes. Furthermore, GLP-1 not only
acted as an incretin to lower blood glucose via stimulation
of insulin secretion from islet β cells but also inhibited gas-
tric emptying and acid secretion, reduced food ingestion
and glucagon secretion [44]. Vilsboll and coworkers [45]
showed that a normal GIP secretion, but reduced post-
prandial concentrations of biologically active GLP-1 in type
2 diabetic patients. Previous studies have indicated that
whereas GLP-1 is strongly insulinotropic in patients with
Type II diabetes mellitus, the effect of GIP is much weaker
or absent [46,47]. In fact, GLP-1 was reported to play a
more important role on normalizing fasting hyperglycemia
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fect of Lr263 on improving hyperglycemia in HFD rats was
mostly attributed to GLP-1 secretion.
Oxidative stress is considered to play an important
role in the pathogenesis of type 2 diabetes [49]. In
addition, oxidative stress is also associated with progres-
sion of hepatic steatosis and advanced liver damage
resulted from degenerative changes in the enzymatic
antioxidant defense system [50,51]. In our present data,
the serum levels of AST and ALT, two critical markers
of liver injury, were increased in HFD rats; meanwhile,
the activities of hepatic antioxidants namely SOD and
GR were decreased in HFD rats. These results demon-
strated that high fructose treatment exhibited deleterious
effects on antioxidant production and subsequently en-
hanced oxidative stress in rats, which then resulted in
liver damage in HFD rats seen in our study. After treat-
ment with Lr263, downregulation of serum AST and
ALT levels and upregulation of hepatic activities of SOD
and GR in HFD rats were noticed. These findings im-
plied that Lr263 consumption significantly reduced both
oxidative stress and liver damage in HFD rats via enhan-
cing hepatic antioxidants expressions. There is consider-
able evidence that hyperglycemia results in the
generation of reactive oxygen species (ROS), ultimately
leading to increased oxidative stress in a variety of tis-
sues. Oxidative stress is supposed to stimulate the pro-
duction of a variety of proinflammatory cytokines, which
may ultimately lead to insulin resistance [52-54]. Both
TNF-α and IL-6, two main proinflammatory cytokines
released by adipose tissue, can inhibit insulin signalling,
and TNF-α may have a crucial role in the development
of insulin resistance in type 2 diabetes [55]. Our present
study revealed that Lr263 administration markedly
suppressed the increased TNF-α and IL-6 production by
adipose tissue in HFD rats, suggesting that Lr263 ame-
liorated insulin resistance through reducing oxidative
stress as well as proinflammatory cytokines production.
The major pathogenesis of metabolic syndrome is the
development of insulin resistance caused by the accumu-
lation of visceral fat which promoted the elevation of
blood pressure, dyslipidemia, and dysregulation of glu-
cose metabolism [56]. Among the target tissues of insu-
lin, liver is the principal regulator of glucose and lipid
metabolism by controlling hepatic glucose production,
glycogen storage, and lipogenesis [56]. As shown in our
study, administration of Lr263 dramatically decreased
the levels important components of metabolic syndrome,
including serum glucose, insulin, LDL, TG, and choles-
terol, enhanced by high fructose treatment. In addition
to serum levels, the increased hepatic levels of TG and
cholesterol treated with high fructose were also found to
be suppressed by oral administration of Lr263. In
present study, our data implicated that administration ofLr263 could improve insulin resistance via downregu-
lation of both serum and hepatic lipid concentrations. To
elucidate the possible mechanisms of Lr263 on suppres-
sion of hepatic lipid accumulation in HFD rats, we
assessed liver mRNA levels of genes involved in lipogen-
esis. Excess fructose consumption is closely associated
with the development of type 2 diabetes due to insulin in-
sensitivity and dyslipidemia. Srebp-1c is a well-known
transcription factor that regulates hepatic fatty acid and
triglyceride biosynthesis by upregulating the expression of
key genes, such as FAS [57]. In addition, dietary fructose
markedly increases the expression of hepatic Srebp-1c,
and FAS in rats [58]. Elvol6 is an elongase that specifically
catalyzes the elongation of saturated and monounsatu-
rated fatty acids with 12, 14, and 16 carbons [59]. Numer-
ous studies have demonstrated that Elvol6 regulated by
SREBP-1, playing an important role in de novo synthesis
of long-chain saturated and monounsaturated fatty acids
in conjunction with FAS [60]. The findings of our study
showed that high fructose treatment markedly induced
lipogenic genes namely s rebp-1c, FAS, and Elvol6 expres-
sions in rat liver. Administration Lr263 counteracted the
increase in hepatic lipogenic genes in HFD rats. These re-
sults suggested that Lr263 consumption not only sup-
pressed hepatic lipid accumulation, but also subsequently
improved insulin resistance in HFD rats.
In contrast to type 1 diabetes, in which there is an ab-
solute insulin deficiency due to destruction of islet cells
in the pancreas, type 2 diabetes is a metabolic disorder
that is characterized by high blood glucose in the con-
text of insulin resistance and relative insulin deficiency.
PPAR-γ, a nuclear receptor, plays a critical role in glu-
cose and lipid metabolism. Moreover, PPAR-γ also plays
an important role in regulating insulin sensitivity and
glucose homeostasis [61]. Glucose transporter proteins,
GLUT1 and GLUT4, the two integral isoforms present
in adipose tissue, play the role of tissue glucose uptake
and regulate body glucose homeostasis [62]. While
GLUT1 is involved in a low intensity of glucose uptake,
GLUT4 plays a critical role in regulation of glucose
homeostasis and functions as a key modulator of glucose
disposal in fat [63]. PPAR-γ activity has been shown to
directly regulate the expression of GLUT4 involving in
regulating insulin-stimulated glucose transport [64]. Our
study demonstrated that a decrease in PPAR-γ mRNA
expression in adipose tissue of HFD rats was observed.
However, Lr263 administration restored the PPAR-γ
mRNA expression reduced by high fructose treatment.
In addition, both GLUT1 and GLUT4 mRNA expres-
sions in adipose tissue of HFD rats were lower than
those of control group. While GLUT1 mRNA expression
remained unchanged, the level of GLUT4 mRNA was
significantly enhanced by Lr263 treatment. These results
implicated that Lr263 may improve insulin resistance,
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stasis in adipose tissue through upregulation of PPAR-γ
and GLUT4 expressions.
Insulin resistance plays a crucial role in hepatic steatosis
[65], which is closely associated with obesity and often ac-
companied by marked abdominal adiposity [66]. Fat accu-
mulation in the liver and insulin resistance cause as well
as potentiate each other, and creating a vicious cycle of
metabolic dysfunction resulting in the development of
hepatic steatosis [67]. Our results from histological ana-
lysis demonstrated that a prominent hepatic steatosis was
observed in HFD rats, whereas administration of Lr263
significantly ameliorated fat accumulation in liver as com-
pared to HFD group. These findings indicated that hyper-
lipidemia and insulin resistance caused by high fructose
treatment were improved by administration of Lr263,
which may ameliorate the development of hepatic stea-
tosis in HFD rats.
Conclusion
Previous studies regarding the therapeutic effectiveness
of Lactobacillus species on diabetes and its complica-
tions were focus on increasing insulin sensitivity [68] or
delaying the onset of glucose intolerance, hyperglyce-
mia, hyperinsulinemia, dyslipidemia, and oxidative stress
[17,19,69]. In line with previous studies, oral administra-
tion of Lr263 significantly improved insulin resistance,
glucose intolerance, oxidative stress, fatty liver, and hep-
atic damages in rats fed with high fructose diet. The
results presented herein not only provided a solid theor-
etical basis regarding how Lr263 exhibited its effective-
ness on treating diabetes, but also shed light on the
development of Lr263 as a promising therapeutic option
for the management of type 2 diabetes.
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